Danaher Corporation $DHR Position Lifted by National Pension Service

National Pension Service grew its stake in shares of Danaher Corporation (NYSE:DHR) by 2.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,500,949 shares of the conglomerate’s stock after purchasing an additional 40,205 shares during the quarter. National Pension Service’s holdings in Danaher were worth $285,901,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of DHR. Hilton Head Capital Partners LLC acquired a new position in Danaher in the fourth quarter worth about $27,000. Clal Insurance Enterprises Holdings Ltd raised its stake in Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after buying an additional 53 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter valued at approximately $25,000. N.E.W. Advisory Services LLC bought a new position in Danaher during the 2nd quarter worth approximately $25,000. Finally, Main Street Group LTD acquired a new position in shares of Danaher in the 1st quarter worth approximately $25,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 0.1%

Shares of NYSE DHR opened at $205.06 on Thursday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a market cap of $144.15 billion, a price-to-earnings ratio of 36.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock’s 50 day simple moving average is $202.55 and its 200 day simple moving average is $192.08.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the business earned $0.77 EPS. The firm’s revenue was up 5.5% on a year-over-year basis. Equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on DHR shares. Stifel Nicolaus lowered their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. TD Cowen dropped their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, DZ Bank began coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.